Skip to main content
. 2021 Oct 23;12(12):3079–3092. doi: 10.1007/s13300-021-01166-z

Table 5.

Sensitivity analysis results (CNY/QALY)

Scenario analysis ICER: flash monitoring vs. SMBG/POCT
T1D T2D
Non-severe and severe hypoglycemia event rate from a Chinese study 31,150 102,664
0% discount rates for costs and health outcomes 66,289 138,868
8% discount rates for costs and health outcomes 41,657 141,198
5-year time horizon 45,315 146,958
Upper limit of 95% CI of non-severe and severe hypoglycemia event disutility 48,262 142,897
Lower limit of 95% CI of non-severe and severe hypoglycemia event disutility 47,022 137,790
Upper limit of 95% CI of SMBG/POCT treatment disutility 51,874 159,280
Lower limit of 95% CI of SMBG/POCT treatment disutility 43,569 123,469
Sensor cost of flash glucose monitoring decreased by 20% 15,892 95,298
Insulin costs increased by 20% 48,512 140,524
Insulin costs decreased by 20% 46,760 140,053
Complication treatment costs increased by 20% 40,359 130,728
Complication treatment costs decreased by 20% 54,914 149,867
SMBG/POCT frequency of 7 times per day 37,106 105,179

CNY Chinese yuan, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio, SMBG/POCT self-monitoring of blood glucose, T1D type 1 diabetes, T2D type 2 diabetes